These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12818400)

  • 1. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation.
    Bea F; Blessing E; Shelley MI; Shultz JM; Rosenfeld ME
    Atherosclerosis; 2003 Apr; 167(2):187-94. PubMed ID: 12818400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering.
    Bea F; Blessing E; Bennett B; Levitz M; Wallace EP; Rosenfeld ME
    Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1832-7. PubMed ID: 12426212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis.
    Bea F; Blessing E; Bennett BJ; Kuo CC; Campbell LA; Kreuzer J; Rosenfeld ME
    Cardiovasc Res; 2003 Oct; 60(1):198-204. PubMed ID: 14522423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
    Martínez-González J; Alfón J; Berrozpe M; Badimon L
    Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
    Alfon J; Guasch JF; Berrozpe M; Badimon L
    Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo.
    Han KH; Ryu J; Hong KH; Ko J; Pak YK; Kim JB; Park SW; Kim JJ
    Circulation; 2005 Mar; 111(11):1439-47. PubMed ID: 15781755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p(53), Bcl-2 and Bcl-xL.
    Qin W; Lu Y; Zhan C; Shen T; Dou L; Man Y; Wang S; Xiao C; Bian Y; Li J
    Cardiovasc Drugs Ther; 2012 Feb; 26(1):23-30. PubMed ID: 22038096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E.
    Wang YX; Martin-McNulty B; Huw LY; da Cunha V; Post J; Hinchman J; Vergona R; Sullivan ME; Dole W; Kauser K
    Atherosclerosis; 2002 May; 162(1):23-31. PubMed ID: 11947894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
    Dol F; Martin G; Staels B; Mares AM; Cazaubon C; Nisato D; Bidouard JP; Janiak P; Schaeffer P; Herbert JM
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):395-405. PubMed ID: 11486244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition.
    Tsuchiya A; Nagotani S; Hayashi T; Deguchi K; Sehara Y; Yamashita T; Zhang H; Lukic V; Kamiya T; Abe K
    Curr Neurovasc Res; 2007 Nov; 4(4):268-73. PubMed ID: 18045152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering.
    Sparrow CP; Burton CA; Hernandez M; Mundt S; Hassing H; Patel S; Rosa R; Hermanowski-Vosatka A; Wang PR; Zhang D; Peterson L; Detmers PA; Chao YS; Wright SD
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):115-21. PubMed ID: 11145942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients.
    Hölschermann H; Hilgendorff A; Kemkes-Matthes B; Schönburg M; Bauer EP; Tillmanns H; Haberbosch W
    Transplantation; 2000 May; 69(9):1830-6. PubMed ID: 10830219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2.
    Tuomisto TT; Lumivuori H; Kansanen E; Häkkinen SK; Turunen MP; van Thienen JV; Horrevoets AJ; Levonen AL; Ylä-Herttuala S
    Cardiovasc Res; 2008 Apr; 78(1):175-84. PubMed ID: 18192240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages.
    Veillard NR; Braunersreuther V; Arnaud C; Burger F; Pelli G; Steffens S; Mach F
    Atherosclerosis; 2006 Sep; 188(1):51-8. PubMed ID: 16321392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulations of CD36 and Calpain-1, Inflammation, and Atherosclerosis by Simvastatin in Apolipoprotein E Knockout Mice.
    Yin M; Liu Q; Yu L; Yang Y; Lu M; Wang H; Luo D; Rong X; Tang F; Guo J
    J Vasc Res; 2017; 54(3):123-130. PubMed ID: 28448973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin blunts endotoxin-induced tissue factor in vivo.
    Steiner S; Speidl WS; Pleiner J; Seidinger D; Zorn G; Kaun C; Wojta J; Huber K; Minar E; Wolzt M; Kopp CW
    Circulation; 2005 Apr; 111(14):1841-6. PubMed ID: 15824212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression and Characterization of the Accelerated Atherosclerosis in Iliac Artery of New Zealand White Rabbits: Effect of Simvastatin.
    Kanshana JS; Khanna V; Singh V; Jain M; Misra A; Kumar S; Farooqui M; Barthwal MK; Dikshit M
    J Cardiovasc Pharmacol; 2017 May; 69(5):314-325. PubMed ID: 28207427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes.
    Lobo SM; Quinto BM; Oyama L; Nakamichi R; Ribeiro AB; Zanella MT; Dalboni MA; Batista MC
    Cytokine; 2012 Oct; 60(1):150-6. PubMed ID: 22658637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation.
    Harja E; Bucciarelli LG; Lu Y; Stern DM; Zou YS; Schmidt AM; Yan SF
    Circ Res; 2004 Feb; 94(3):333-9. PubMed ID: 14670837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.